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Abstract 28 
The embryonic transcription factors TWIST1/2 are frequently overexpressed in cancer, acting 29 
as multifunctional oncogenes. Here we investigate their role in neuroblastoma (NB), a 30 
heterogeneous childhood malignancy ranging from spontaneous regression to dismal 31 
outcomes despite multimodal therapy. We first reveal the association of TWIST1 expression 32 
with poor survival and metastasis in primary NB, while TWIST2 correlates with good prognosis. 33 
Secondly, suppression of TWIST1 by CRISPR/Cas9 results in a reduction of tumor growth and 34 
metastasis in immunocompromised mice. Moreover, TWIST1 knockout tumors display a less 35 
aggressive cellular morphology and a reduced disruption of the extracellular matrix (ECM) 36 
reticulin network. Additionally, we identify a TWIST1-mediated transcriptional program 37 
associated with dismal outcome in NB and involved in the control of pathways mainly linked to 38 
the signaling, migration, adhesion, the organization of the ECM, and the tumor cells versus 39 
tumor stroma crosstalk. Taken together, our findings suggest TWIST1 as novel therapeutic 40 
target in NB.  41 
 42 
Introduction  43 
Neuroblastoma (NB) is the most prevalent solid extra cranial tumor of childhood1. While it 44 
accounts for approximately 5% of all pediatric cancer, it contributes for 12% of all pediatric 45 
deaths2,3. Primary tumors can arise along the sympathetic chains and in the adrenal medulla1,4. 46 
NB is both biologically and clinically heterogeneous. It spans from tumors with favorable 47 
biology that can spontaneously regress, to high-risk disease frequently relapsing or refractory 48 
to multimodal treatments and responsible for 50-60% of mortality1,4. Prognosis is associated 49 
with a number of factors, including International Neuroblastoma Risk Group (INRG) stages, 50 
age at diagnosis, histopathological classification, the presence of segmental chromosomal 51 
alterations1,5, the activation of telomere maintenance mechanisms6,7 and somatic mutations in 52 
the RAS/MAPK and p53 pathway7. Amplification of the proto-oncogene MYCN (MNA) is 53 
present in more than 20% of primary NB and in 40-50% of patients with high-risk (HR) disease. 54 
It is the most important biological predictor of a poor clinical response2.  55 
As for most pediatric cancers, the origins of NB can be linked back to defects in key cell 56 
signaling pathways during embryonic development8. NB originates from trunk neural crest (NC) 57 
progenitors that are committed to give rise to the sympathetic nervous system4,8. NC cells are 58 
a transient population of multipotent cells that, in the developing embryo upon an epithelial to 59 
mesenchymal transition (EMT), delaminate, migrate and differentiate into a broad lineage 60 
repertoire9.  61 
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TWIST1/2 transcription factors are among the master regulators of the EMT process10,11. 62 
TWIST1/2 are highly conserved and guide developmental programs including cell lineage 63 
determination and differentiation, and are essential for organogenesis10,12. In humans, 64 
germline mutations of the TWIST1 gene are responsible for the Saethre-Chotzen syndrome 65 
(SCS), characterized by limb abnormalities, facial dimorphism, and premature fusion of cranial 66 
sutures13. Reactivation and aberrant functions of TWIST1/2 have been found in several 67 
carcinomas. Both TFs provide cells with critical properties including self-renewal capabilities, 68 
resistance to oncogene-induced failsafe programs and invasive capabilities thus promoting 69 
cancer initiation and progression toward a metastatic disease10,11,14. Since TWIST1/2 are active 70 
in NC cells, where they play a key role in driving EMT and migration, the study of their functions 71 
in NB is particularly important to better understand the neuroblastomagenesis, as distant 72 
metastases are already present by the time of diagnosis for the disseminated forms of this 73 
disease. So far, the role of TWIST1/2 in NB is still largely unknown. Upregulation of TWIST1 74 
is found in NB with MNA and in a subset of no-MNA tumors, overexpressing MYCN or MYC15-75 
17. In addition, TWIST1 protects NB cells from the pro-apoptotic effects mediated by MYCN, 76 
through the inhibition of the ARF/p53 pathway and cooperates with MYCN in NB to uphold 77 
both in vitro cell proliferation and in vivo tumor growth15,18. Recently, TWIST1 was also 78 
identified as a key regulator of MYCN-driven gene regulation through their cooperative binding 79 
on enhancers18.  80 
In this study, we initially revealed the correlation between the expression of TWIST1 and NB 81 
clinical prognostic factors in silico on primary NB gene expression datasets and in tumor tissue 82 
microarrays. Using an in vivo model for transcriptomic analyses, we then unveiled the impact 83 
of CRISPR/Cas9-mediated TWIST1 silencing on NB tumor growth, metastatic dissemination 84 
and the reorganization of the tumor microenvironment (TME). 85 
Results  86 
High levels of TWIST1 RNA expression are associated with poor outcomes in patients 87 
with NB.  88 
In silico analysis using the CCLE database (https://portals.broadinstitute.org/ccle) shows that 89 
NB displays the highest levels of TWIST1 expression among 40 cancer cell lines, whereas 90 
TWIST2 is barely detected (Supplementary Fig. 1a). To further evaluate whether the 91 
expression levels of TWIST1/2 correlate with patient outcomes and NB prognostic factors, we 92 
analyzed two large clinical cohorts of primary NB tumors using the R2: Genomics Analysis and 93 
Visualization Platform (http://r2.amc.nl) (SEQC19, n = 498; Kocak20, n = 649). In both datasets, 94 
a high level of TWIST1 transcript strongly correlates with both a reduced overall survival (OS) 95 
(Fig. 1a; Supplementary Fig. 1b) and event-free survival (EFS) (Supplementary Fig. 1c). 96 
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Moreover, the expression of TWIST1 was more elevated in MNA NBs compared to those 97 
without MNA (Fig. 1b, Supplementary Fig. 1d); and in higher stage tumors (stages 3 and 4 vs 98 
1 and 2; stage 4 vs 4s) (Supplementary Fig. 1e).  99 
To understand whether TWIST1 could be a prognostic factor in NB, we stratified patients of 100 
the SEQC dataset according to the level of TWIST1 expression and either the MYCN status 101 
(Fig. 1c) or risk (HR vs low-risk (LR); Supplementary Fig. 1f). For MNA or HR patients, TWIST1 102 
expression level had no impact on the EFS. Conversely, for no-MNA and LR cases, a high 103 
level of TWIST1 expression was associated with a reduced outcome, likewise the MNA or the 104 
HR status, hinting to a possible role for TWIST1 as a prognostic factor for these patients. As 105 
opposed to TWIST1, in the two same datasets, higher levels of TWIST2 were associated with 106 
both a better OS and EFS in NB patients (Supplementary Fig. 1g). Moreover, TWIST2 107 
expression was increased in no-MNA NB (Supplementary Fig. 1h).  108 
TWIST1 expression patterns reveal a correlation with poor prognostic factors in NB. 109 
We examined the expression levels of TWIST1/2 proteins in a NB tissue microarray (TMA) 110 
(Table 1). In control sympathetic ganglia (SG), TWIST1 was not detected while TWIST2 was 111 
present with moderate intensity in 46% of SG (Fig. 2a; Table 1). TWIST1 expression was 112 
statistically significantly higher in tumors associated with poor prognosis: stages 3-4 vs stages 113 
1-2; stage 4 vs 4s; tumors with MNA vs no-MNA; and in patients older than 18 months at the 114 
diagnosis (Fig. 2b; Table 1). On the other hand, the expression of TWIST2 was higher in 115 
tumors with better prognosis: stages 1-2 vs stages 3-4 and in patients with no-MNA vs MNA 116 
(Fig. 2b; Table 1). However, no statistically significantly differences in TWIST2 expression 117 
were observed in stage 4s vs stage 4 or in relation with age at diagnosis (Fig. 2b). Finally, 118 
TWIST1 was frequently expressed in metastases (76% positive, median score=0.95), while 119 
TWIST2 expression was uncommon (30% positive, median score=0.31) (Fig. 2a; Table 1).  120 
TWIST1 KO impairs the neurosphere-forming ability of NB cells.  121 
To investigate the contribution of TWIST1 in the aggressive features of NB, three cell lines, 122 
either MNA (LAN-1 and SK-N-Be2c) or non-NMA (NB-1), were chosen for a TWIST1 knockout 123 
(KO) through CRISPR/Cas9. A complete KO of the wild type (wt) TWIST1 protein expression 124 
was obtained with the sgTWIST1 #1 for the three cell lines that from now on will be referred to 125 
as sgTWIST1 cells (Supplementary Fig. 2a, b). TWIST1 KO did not significantly affected the 126 
2D growth property of NB cell lines (Supplementary Fig. 2c), however it reduced the 127 
neurosphere-forming ability of the three NB cell lines (Fig. 3a). Consequently, the number of 128 
sgTWIST1 cells recovered from primary neurospheres was statistically significantly lower 129 
compared to Control cells (Fig. 3a), indicating the role played by TWIST1 in propagating a 130 
highly tumorigenic subpopulation of NB cells.  131 
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TWIST1 KO delays tumor growth of NB xenotransplantation and extends survival in 132 
mice.  133 
Next, we investigated the contribution of TWIST1 in the tumorigenicity of NB cells. In three 134 
independent experiments, athymic Swiss nude mice were injected with the SK-N-Be2C Control 135 
and sgTWIST1 cells either orthotopically (500’000 cells for ortho_1 and 50’000 cells for 136 
ortho_2) or subcutaneously (sc, 250’000 cells). In all the three models, the growth of the 137 
sgTWIST1 tumors was severely delayed compared to Controls thus extending sgTWIST1 mice 138 
survival (Fig.3b, Supplementary Fig. 3a). In particular, in the first orthotopic experiment 139 
(ortho_1), 26 days after the injection, tumors in Control mice were already above the pre-140 
determined volume for sacrifice while in the sgTWIST1 mice they were still in the lag phase 141 
(Fig. 3c). In the second orthotopic experiment (ortho_2), we observed a significant delay in the 142 
time of both SK-N-Be2c-sgTWIST1 tumor initiation and tumor growth (Fig.3d). Furthermore, 143 
25 days after sc injections, the size of Control tumors was ~10 times larger than sgTWIST1 144 
tumors. The latter required four additional weeks before reaching the size limit for sacrifice 145 
(Supplementary Fig.3b). Finally, in both orthotopic experiments we observed SK-N-Be2c-146 
Control tumors invading the vena cava (n=3/6: ortho_1; n=3/8: ortho_2) (Supplementary Fig. 147 
3c), whereas no invasion was detected in the sgTWIST1 mice group.  148 
TWIST1 KO diminishes the malignant phenotype of tumors and decreases 149 
intrapulmonary macrometastasis 150 
In both orthotopic in vivo models, Control tumors presented histological features corresponding 151 
to undifferentiated or poorly differentiated cells, while sgTWIST1 tumors were more 152 
differentiated (Fig.4a). Moreover, Control cells showed a lower degree of cohesion and a 153 
higher degree of immune cell infiltration compared to the sgTWIST1 tumors (Fig. 4a). We 154 
analyzed the effects of TWIST1 KO on the pattern of collagen III/reticulin fibers, which 155 
contribute to the ECM. Throughout all the three in vivo models, in Control tumor tissues the 156 
continuity of the reticular fiber framework was lost in extensive tumor areas, and we observed 157 
irregular thickening and fraying of fibers mainly at the borders of tumors (Fig. 4b, 158 
Supplementary Fig. 4a). In contrast, the sgTWIST1 tumors were characterized by a preserved 159 
reticulin mesh, resembling that of the normal adrenal gland (AG) (Fig. 4b, Supplementary Fig. 160 
4a). This effect was not altered by the tumor size at the sacrifice (Supplementary Fig. 4b).  161 
We speculated that the abovementioned ECM modifications associated with the expression of 162 
TWIST1 could be responsible for a “pro-neoplastic” stromal phenotype, offering less resistance 163 
for the invasive cells to escape the primary tumor site and form metastasis21. Therefore, the 164 
lungs of the ortho_2 experiment mice were stained by H&E and anti-mCherry for the presence 165 
of intrapulmonary metastasis (Fig. 4c). We could observe a decrease in the number of 166 
intrapulmonary micrometastases (area (A) <1000 µm2) in the sgTWIST1 group, though this 167 
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difference was not statistically significant (Fig. 4d). Conversely, the number of intrapulmonary 168 
macrometastases (A> 1000 µm2) in the sgTWIST1 mice was statistically significantly reduced 169 
(Fig. 4d) as a single one was detected in only 1/10 sgTWIST1 mouse (2.3x103 µm2) (Fig. 4c, 170 
lower panel), whereas 6/8 Control mice had multiple macrometastases (mean 171 
macrometastases size/mice: 5.1x105µm2). 172 
Identification of distinct transcriptional program regulated by TWIST1 and MYCN in NB 173 
cells 174 
Transcriptomic analyses of SK-N-Be2c-Control and –sgTWIST1 cells and their derived-175 
ortho_1 tumors were performed by RNAseq. Principal Component Analysis (PCA) revealed a 176 
high degree of segregation of the transcriptomic profiles of Control and sgTWIST1 for both 177 
cells and ortho_1 tumors, enabling the accurate identification of genes that are differentially 178 
expressed (DE) (Fig. 5a). We identified 2342 DE genes (1401 up- and 941 down regulated) in 179 
SK-N-Be2c cells (Supplementary Fig. 5a; Supplementary Data 1) and 2013 (1003 up- and 180 
1010 down regulated) in the SK-N-Be2c ortho_1 tumors (Fig. 5b; Supplementary Data 1), with 181 
1213 found in common (Supplementary Data 1). Gene ontology (GO) analyses for the DE 182 
genes in cells and in tumors reported a number of significantly enriched terms related to 183 
signaling, nervous system development, migration, proliferation, ECM organization and 184 
adhesion for both biological processes (BP) and cellular components (CC) (Fig. 5c; 185 
Supplementary Fig. 5b; Supplementary Data 2).  186 
As downregulation of MYCN was observed upon transient TWIST1 silencing in SK-N-Be2c, a 187 
decrease in MYCN expression level could be, in part, responsible for the deregulation of the 188 
transcriptional program observed in our ortho tumors18. To exclude this possibility, we analyzed 189 
the expression level of MYCN protein by immunoblotting in tumors coming from the three in 190 
vivo experiments. In all sgTWIST1 tissues, we detected an increase in the level of MYCN 191 
protein compared to the Control counterpart (Supplementary Fig. 5c) although this increase 192 
was not sufficient alone to promote and sustain a more aggressive phenotype in the sgTWIST1 193 
tumors.  194 
To compare the transcriptional program defined by TWIST1 with the one induced by MYCN in 195 
SK-N-Be2c cells, we reanalyzed RNAseq data obtained upon MYCN shutdown using the BET-196 
bromodomain inhibitor JC118. GO analyses performed on DE genes highlighted an enrichment 197 
of gene sets mainly involved in the regulation of cell cycle and the DNA replication for both BP 198 
and CC, thus suggesting distinct functions for the two TFs (Fig. 5d; Supplementary Fig. 5d; 199 
Supplementary Data 3 and 4). 200 
 201 
 202 
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A TWIST1-mediated gene expression signature is associated with poor outcome in NB  203 
We combined our ortho_1 transcriptomic analysis with RNAseq data of primary NB tumors to 204 
identify a TWIST1-associated gene signature relevant in primary NB. Using the ‘R2 Platform, 205 
we first listed the genes either correlated (R positive) or anti-correlated (R negative) with 206 
TWIST1 expression in the SEQC dataset of NB tumors (n=7737 genes with R absolute value 207 
>0.225, Supplementary Fig. 6a). Second, we crossed this list of genes with the 2011 DE genes 208 
between SK-N-Be2c-Control and -sgTWIST1 tumors, either up- (FC positive) or down-209 
regulated (FC negative) by TWIST1. We found 763 genes in common (Fig. 6a; Supplementary 210 
Data 5) among which we selected those that had both R and FC either positive (172 genes) or 211 
negative (317 genes). We called these resulting 489 genes the TWIST1-signature (Fig. 6b; 212 
Supplementary Data 5). Using the same SEQC dataset, we analyzed the clinical significance 213 
of the signature, and observed that genes correlated with TWIST1 in NB patients and 214 
upregulated by TWIST1 in ortho_1 tumors (R and FC positive) mostly had an elevated level of 215 
expression in high-risk, more advanced stages and MNA tumors. In addition, these tumors 216 
displayed a low level of expression of genes downregulated in the TWIST1-signature (Fig. 6c). 217 
Finally, an elevated expression level of the TWIST1-signature was associated in the SEQC 218 
and Kocak datasets with a poor OS and EFS for both the complete patient cohorts and the 219 
sub-cohorts without MNA (Fig. 6d, 6e; Supplementary Fig. 6 b, 6c).  220 
Among the top deregulated genes in the TWIST1-signature, several have crucial roles during 221 
embryonic development, in particular for the correct development of the nervous system 222 
(BMP7, FGF2, DTNA, MATN2, PCDHA1, PMP22, SCL1A3). Moreover, most of the top up-223 
regulated genes are involved in the organization of both TME (PDGFRA, VCAN, BMP7, FGF2) 224 
and ECM (ADAMST19, PCOLCE); in the EMT process (BMP7, TRIM28), as well as in cell 225 
proliferation (FGF2 and PDGFRA) and apoptosis (BMP7) (Fig. 7a). Besides, among the top 226 
genes down-regulated in the TWIST1 signature, some are involved in neuronal differentiation 227 
(PIRT), and  various are tumor suppressor genes (SYT13, FAM134B, PMP22, C7 and MATN2) 228 
Fig. 7a). Several transcripts belonging to the TWIST1-signature were chosen, based on their 229 
degree of differential expression and their biological function, for validation by RT-qPCR and 230 
WB/IHC. We confirmed that VCAN, PDGFRA, TRIM28, PCOLCE and ADAMTS19 genes were 231 
upregulated by TWIST1, as their RNA and/or protein expression levels were increased in SK-232 
N-Be2c-Control relative to -sgTWIST1 tumors, while the opposite was true for the genes 233 
downregulated by TWIST1 (PIRT and SYT13) (Fig. 7b-d; Supplementary Fig. 7a, 7b; 234 
Supplementary Fig. 8a-c).  235 
TWIST1 alters the level of expression of genes involved in tumor-stroma crosstalk. 236 
Cancer cells establish a reciprocal intercellular signaling network and communicate with 237 
stromal and immune cells via the production of soluble paracrine factors and their cognate 238 
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receptors. This complex signaling network shapes the TME to sustain cancer cell proliferation 239 
and invasion. To address whether TWIST1 alters the expression of factors involved in cell-cell 240 
communication, DE genes annotated as cytokines, chemokines, growth factors, inflammatory 241 
mediators and their receptors, as well as integrin and their ligands were extracted from SK-N-242 
Be2c tumor transcriptome. This TWIST1-tumor-stroma signature is composed by 77 DE 243 
genes, 33 up- and 44 down-regulated (Fig. 8a, Supplementary Data 6). Several play a pivotal 244 
role in the regulation of focal adhesion (EGFR, ITGA11, ITGA6, PDGFRB); cell migration 245 
(COL5A1, ITGAV, ITGB3, PDGFRB, TGFB1); proliferation (FGF1, FIGF, IFI16); angiogenesis 246 
(ACKR3, ACVRL1, EGFL7, FGF1, FGFR2, FIGF); and inflammatory and immune responses 247 
(NGFR, TNF, TNFRSF1A, TNFRSF1B, TNFRSF4, TNFRSF9, TNFSF12, TNFSF13, 248 
TNFSF4). A high level of expression of the TWIST1-tumor-stroma signature was associated 249 
with a poor OS and EFS of NB patients both in the SEQC (Fig. 8b) and the Kocak dataset 250 
(Supplementary Fig. 9a).  251 
To validate the tumor-stroma signature at the protein level and further characterize TWIST1-252 
mediated alterations in cell-cell communication, we analyzed the secretome of SK-N-Be2c-253 
Control and -sgTWIST1 cells in vitro by HPLC/Tandem MS using their conditioned media (CM) 254 
containing both secreted proteins and extracellular vesicles released by tumor cells. These 255 
secretomes contained 673 DE peptides (304 up- and 369 down-regulated) (Fig. 8c; 256 
Supplementary Data 7) that corresponded to 678 genes. GO analyses revealed an enrichment 257 
of BP linked to nervous system development, signaling, response to stimuli, migration, and 258 
proliferation (Supplementary Fig. 9b; Supplementary Data 8).  259 
Crossing secretome and transcriptome data from both cells and tumors, we identified 131 260 
commonly deregulated terms, whereas 75 and 55 were uniquely shared between the 261 
secretome and either the cell or tumor transcriptome, respectively (Fig. 8d; Supplementary 262 
Data 7). Finally, after crossing the TWIST1-tumor-stroma signature with the secretome of cells, 263 
we could identify 17 commonly DE terms, among which 14 were also found to be in common 264 
with the transcriptome of cells (Fig. 8e). Most of the commonly deregulated terms were up 265 
regulated by TWIST1 and annotated as growth factors, and for all terms but COL5A1 and VGF, 266 
the impact of TWIST1 on RNA and protein expression was always found to be correlated. 267 
Myofibroblast-associated gene expression is reduced in the stroma of sgTWIST1 268 
orthotopic tumors. 269 
Among the terms deregulated in the abovementioned tumor-stroma signature, several are also 270 
known for being involved in the crosstalk between cancer cells and the resident and recruited 271 
stromal cells (i.e. TGFB1, HGF, FGF, FGFR, EGFR, PDGFR, CXCL12) and thus they could 272 
mediate a TME sustaining the tumor growth22. One of the main stromal changes within a pro-273 
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tumorigenic TME is the appearance of cancer-associated fibroblasts (CAFs), playing a critical 274 
role in arranging the “soil” within which tumor cells proliferate23. To verify whether we could 275 
detect the presence of CAFs in the tumor stroma, the ortho_1 RNAseq data were aligned with 276 
the murine genome. Between Control and sgTWIST1 tumors, 89 stromal genes were found to 277 
be DE(69 up- and 20 down-regulated) (Fig. 9a; Supplementary Data 9). Genes up-regulated 278 
in the stroma of TWIST1 expressing Control tumors showed a significant enrichment of muscle 279 
contraction-related terms (Fig. 9a; Table 2). This was defined as the myofibroblastic signature 280 
(n=36 genes) according to the literature24-27. GO analysis for the murine DE genes reported a 281 
number of statistically significantly enriched terms related to sarcomere organization and 282 
muscle contraction (Fig. 9b, Supplementary Data 10), supporting a TWIST1-mediated 283 
recruitment and activation of myofibroblasts. 284 
Besides, among the up-regulated genes, we noticed the Macrophage Receptor with 285 
Collagenous Structure (Marco), which defines a subtype of alternatively-activated M2 tumor-286 
associated macrophages (TAMs) with immunosuppressive functions and involved in tumor 287 
progression28. Six up-regulated genes of the myofibroblastic signature (Pvalb, Neb, Acta1, Ttn, 288 
Myh1, Msln) (Supplementary Fig. 10a) and Marco were confirmed by RT-qPCR. For the 289 
selected genes of the signature, a reduction in their RNA expression levels was observed in 290 
both ortho_sgTWIST1 tumor stroma only, and were undetectable in the tissues from the sc 291 
tumors (Fig. 9c, Supplementary Fig. 10b). The reduced RNA expression level of Marco in 292 
sgTWIST1 tumor stroma was validated in all the three in vivo models (Fig. 9c, Supplementary 293 
Fig. 10b). Finally, qualitative validation by IHC with the CAF marker fibroblast-activation protein 294 
(Fap) confirmed the presence of CAFs in both Control and sgTWIST1 ortho_1 tumors (Fig. 295 
9d).  296 
To analyze the potential interactions existing between the TWIST1-associated tumor-stroma 297 
signature and the DE stromal genes, a protein-protein interacting (PPI) network was 298 
constructed using the STRING website (https://string-db.org/).The two groups of DE genes 299 
clustered separately and had a high level of linkage both among genes of each category and 300 
reciprocally (Fig. 10). Two stromal genes reported as myofibroblastic markers, Acta1, 301 
belonging to the actin family and Actn2, a member of the spectrin superfamily, were strongly 302 
linked to the network of myofibroblastic genes and connected with the tumor gene cluster, via 303 
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Discussion 308 
In this study, we discovered a role for the embryonic TFs TWIST1 and TWIST2 as prognostic 309 
factors in NB. We could reveal the contribution of TWIST1 in enhancing primary and secondary 310 
tumor growth and in mediating an aggressive phenotype in in vivo NB xenografts. Furthermore, 311 
we identified a TWIST1-associated transcriptional signature, which correlated with outcomes 312 
in human primary tumors and activated the TME in an orthotopically-derived xenograft murine 313 
model.  314 
TWIST1 and TWIST2 have previously been described as playing a distinct role during 315 
embryonic development and having anti-correlated transcriptional expression patterns in 316 
spontaneous focal mammary tumors in mice and in human melanoma, colon, kidney, lung and 317 
breast cancer31. In this study, we show their opposite expression pattern in primary NB and 318 
their antithetical prognostic value, highlighting that theTWIST1 expression was correlated with 319 
unfavorable NB prognostic factors, metastasis and poor survival. These findings are in line 320 
with prior studies conducted on non-pediatric cancers showing the overexpression of TWIST1 321 
in high grade and invasive/aggressive breast, bladder, cervical, ovarian and hepatocellular 322 
cancers where it might also serve as prognostic factor for poor survival32. Moreover, we 323 
confirmed previous data showing the association of TWIST1 with MNA NB on larger cohorts 324 
of patients15,16. Furthermore, TWIST2 was mainly detected in normal tissues and in NB with 325 
better prognosis. These results are in contrast with those obtained by others, showing an 326 
association between the upregulation of TWIST2 and a more aggressive tumor phenotype33-327 
36. Importantly, we identified TWIST1 as a valid candidate in predicting the poor outcome of 328 
patients with no-MNA or LR NB, in the same way as the amplification of MYCN or the HR 329 
classification. 330 
Our in vivo investigations on the biological effects of TWIST1 reveal that its loss delays the 331 
primary tumor initiation and growth of NB, regardless of the number of cells and the injection 332 
site. These data are aligned with prior evidence showing that the suppression of TWIST1 333 
hampers the growth of primary skin papilloma induced by carcinogens37; and that the 334 
pharmacological inhibition of the Twist-BRD4-Wnt5a signaling axis results in the reduction of 335 
tumorigenicity of basal-like breast cancer38. Moreover, the overexpression of TWIST1 336 
accelerates tumor establishment and growth of MCF-7-derived breast cancer and transforms 337 
mouse embryonic fibroblasts in cells with high tumorigenic potential31,39. In contrast with these 338 
findings, TWIST1 was shown as nonessential for primary tumor initiation and growth in several 339 
in vivo murine models for breast cancer, pancreatic ductal adenocarcinoma and hepatocellular 340 
carcinoma, although it seems to play a pivotal role in driving cells migration and invasion14,40,41. 341 
Taken together, these antithetical findings suggest that the role of TWIST1 in carcinogenesis 342 
might depend upon the tumor settings as well as on oncogenic drivers.  343 
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In our experiments, TWIST1-expressing tumors displayed a phenotype typical of less 344 
differentiated NBs. Additionally these tumors were characterized by abundant fascicules of 345 
spindle-shaped cells, typical of a mesenchymal-like morphology. The role played by TWIST1 346 
in driving the EMT and in maintaining cells in a mesenchymal state has been widely 347 
documented as part of both the morphogenesis during embryonic development, and in the 348 
pathogenesis of multiple types of invasive cancers41-44. Moreover, several studies demonstrate 349 
an association between the EMT and the acquisition of stem-like characteristics in normal and 350 
neoplastic epithelial tissues, identifying in TWIST1 the molecular linker between these two 351 
biological processes45-47. In our study, TWIST1-expressing NB cells were able to grow in vitro 352 
as neurospheres, known to be enriched in tumor-initiating cells (TIC) exhibiting stem-like 353 
features48. Furthermore, our data reveals a role for TWIST1 in metastatic dissemination in NB, 354 
as an increase in the number and in the size of pulmonary metastases was observed in Control 355 
mice. In fact, the decrease of the invasive mesenchymal-type cells in the sgTWIST1 tumors 356 
and the reduced ability of sgTWIST1 cells to maintain the TIC population could at least in parts 357 
explain the reduction in the number of pulmonary micrometastases observed in sgTWIST1 358 
mice. Moreover, the suppression of TWIST1 also had an impact on the last step of the 359 
metastatic cascade, the colonization, consisting in the growth of micrometastases into 360 
macroscopic metastases, that lies on the self-renewal capability and the proliferative potential 361 
of invading cells.   362 
The ECM is another key player in promoting tumor invasion and metastasis. Disruption and 363 
stiffness of this framework has been demonstrated to contribute to malignant transformation 364 
and cancer progression by destabilizing the cell–cell adhesions and promoting cell 365 
invasion21,49. In Control tumors expressing TWIST1, we observed a disruption of the reticulin 366 
mesh, one of the main components of the ECM, and an increase in their density along the 367 
tumor border. In contrast, sgTWIST1 tumors preserved a nest-like arrangement of thin reticular 368 
fibers, as observed in the normal adrenal gland. Interestingly, a disorganized and cross-linked 369 
reticulin network was associated with poor NB prognosis, and a morphometric classification 370 
based on variations of both blood vessels and reticulin fibers shape and size was proposed to 371 
identify ultra-high risk NB patients50. The involvement of TWIST1 transcriptional targets in the 372 
degradation/remodeling of the ECM has been demonstrated in both normal embryonic 373 
development as well in cancer21,42,51-53. In our orthotopic model, we found several genes 374 
involved in the organization of the ECM and the TME, such as VCAN, ADAMTS19, PDGFRA, 375 
TRIM28 and PCOLCE, among the top 20 upregulated by TWIST1, suggesting a role for 376 
TWIST1 in defining a permissive microenvironment contributing to the survival and 377 
maintenance of cancer stem-like cells. PCOLCE is a direct transcriptional target of TWIST1 378 
and is implicated in the regulation of collagen deposition during both early craniofacial 379 
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development and in osteosarcoma, where it promotes tumor growth, cell migration and 380 
invasion42,54  . In our study using two cohorts of primary NB, PCOLCE was the gene presenting 381 
the highest correlation with TWIST1 expression regardless of the amplification status of 382 
MYCN, suggesting a role for TWIST1 in the control of PCOLCE expression also in primary NB.  383 
For the first time, we identified a NB-associated TWIST1-signature by combining the 384 
transcriptomic data of orthotopic tumors with that of primary tumors. Importantly, an elevated 385 
expression of this signature was found in MNA and HR tumors, and it was associated with poor 386 
survival in the entire NB datasets and their sub-cohorts without MNA. In addition, a subgroup 387 
of TWIST1-target genes involved in shaping the interface between tumor cells and its stroma 388 
could be extracted, which we named TWIST1-tumor-stroma signature. Both signatures 389 
induced by TWIST1 were linked to poor survival in silico, indicating their biological relevance 390 
and confirming the functional role of TWIST1 in NB pathogenesis. 391 
The cooperation between TWIST1 and MYCN in defining a transcriptional program in NB 392 
supporting in vitro cell proliferation and in vivo tumor growth has already been shown15,18. Using 393 
our results and previous published findings on NB, we conclude that these TFs seem to 394 
orchestrate distinct functions.  Indeed, GO analysis on our transcriptomic data revealed that 395 
suppression of TWIST1 in SK-N-Be2c cells and tumors mainly deregulated pathways involved 396 
in signaling, nervous system development, migration, adhesion, ECM organization, and cell 397 
proliferation. Interestingly, these pathways were also principally deregulated by the genes 398 
enriched in the TWIST1-signature. On the other side, GO analysis performed on RNAseq data 399 
of SK-N-Be2c cells downregulated for MYCN through JC118 highlighted a major role for MYCN 400 
in controlling the cell cycle regulation and DNA replication. Similar pathways were also 401 
identified upon MYCN silencing through JC1 or shRNA in MNA NB cell lines 55, thus confirming 402 
a predominant role for this TF in supervising mostly the proliferation of cells.  403 
There are several limitations in our study. First, the use of only one NB cell line to obtain our 404 
in vivo model could represent an issue in the wider relevance of our findings. Although SK-N-405 
Be2c cells are commonly used for NB research, they in fact might not fully represent the biology 406 
and diversity of the disease itself. Thus, our observations about the role of TWIST1 in 407 
enhancing NB tumor aggressiveness remain to be verified using NB cell lines without MNA as 408 
well as primary NB cells. Second, RNAseq analysis was performed on tumors of the ortho_1 409 
experiment, which did not give rise to macroscopic metastases. This was probably caused by 410 
extremely rapid tumor growth, which might have prevented the formation of macrometastases. 411 
However, this model is suitable for appreciating the effects of TWIST1 on tumor growth 412 
capacity and phenotypic features as well as on TME remodeling. Moreover, the main 413 
deregulated genes and pathways were consistently altered by TWIST1 between SK-N-Be2c 414 
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is 
The copyright holder for this preprintthis version posted March 22, 2021. ; https://doi.org/10.1101/2021.03.22.435811doi: bioRxiv preprint 
cells and ortho_1 tumors, and the most relevant genes were confirmed in the ortho_2 tumors.  415 
Importantly, the biological relevance of the transcriptional program defined by TWIST1 in the 416 
SK-N-Be2c ortho_1 xenografts were validated in human primary NB, with the identification of 417 
a TWIST1-associated signature and a tumor-stroma signature, both displaying a strong 418 
prognostic impact in two cohorts of NB patients. Third, in our study we only focused on the 419 
incidence of metastases in the lungs of mice, which occurs in approximately 4% of children 420 
with newly diagnosed NB56. We did not detect macrometastases in the liver, one of the most 421 
frequent sites of infiltration in children together with bone marrow, bone, and lymph nodes. 422 
Fourth, the unambiguous identification of the stromal counterpart activated by the tumor-423 
stroma signature remains challenging. Our transcriptomic data suggest an enrichment of M2 424 
TAM and of myofibroblasts, the most abundant stromal cells supporting tumor progression, in 425 
TWIST1-positive xenografts. The marked connection observed between the TWIST1-tumor-426 
stroma signature and the stromal DE genes by STRING analysis further support their role in 427 
mediating the NB-associated alterations in the tumor stroma. However, the qPCR validation of 428 
the stromal genes belonging to the myofibroblastic signature was hampered by sometimes 429 
extremely low/undetectable expression levels. This was probably due to the very limited 430 
number of stromal cells present in whole tumor lysates. Single cell sequencing could further 431 
facilitate the characterization of the impact of TWIST1 on stroma composition. Moreover, it 432 
could be argued that an immunocompromised mouse model does not represent the most 433 
suitable setup to study TME components. Genetically engineered models spontaneously 434 
developing tumors or humanized mouse NB models could represent other valid alternatives to 435 
recapitulate the TME composition in NB57. Finally, precisely identifying CAF by IHC remains 436 
difficult due to the lack of specific myofibroblast markers, a common issue in all studies.  437 
In summary and for the first time, our study revealed the prognostic significance of TWIST1 438 
and TWIST2 in NB. The biological impact of TWIST1 on tumor growth and metastatic formation 439 
capacity was associated with alterations in the ECM composition and with the establishment 440 
of a TME supportive of tumor growth and progression. The transcriptional program activated 441 
by TWIST1 in our in vivo model of NB further supported these findings and its validation in 442 
primary NB unveiled a correlation with HR disease and poor prognosis. All our findings strongly 443 
indicate a very promising role for targeting TWIST1 in the therapy of HR or relapsed/refractory 444 




.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is 
The copyright holder for this preprintthis version posted March 22, 2021. ; https://doi.org/10.1101/2021.03.22.435811doi: bioRxiv preprint 
Methods  449 
Cancer Cell Line Encyclopaedia (CCLE) database analysis 450 
The CCLE database (https://portals.broadinstitute.org/ccle) was used to compare the mRNA 451 
expression level of TWIST1 and TWIST2 in a range of 36 different cancer types (Affymetrix 452 
arrays: Affimetrix Human Genome U133, Plus 2.0). Quality filtering and normalization were 453 
performed using Robust Multi-array Average (RMA) and quantile normalization.  454 
Tumor Microarray (TMA) and Immunohistochemistry 455 
The TMA was composed by 72 primary tumors, 25 matched metastases and 44 matched 456 
control normal tissues (13 sympathetic ganglia and 31 adrenal glands) (Table 1) obtained from 457 
72 patients diagnosed with NB between July 1988 and November 2001 treated and followed 458 
at the Bicêtre hospital (Le Kremlin-Bicêtre) and the Gustave Roussy Institute (Villejuif). 459 
Immunohistochemical study on patient tissues was performed after patients’ informed consent 460 
and according to the ethical regulations of the institution. On average, 4 tissue cores with a 0.6 461 
mm diameter were obtained and transferred into a recipient paraffin block using a tissue 462 
arrayer (Alphelys: Beecher Instruments Micro-Array Technology, Plaisir, France). TMA 463 
sections 5-μm were made on Benchmark XT Ventana (ROCHE Diagnostics).  After dewaxing, 464 
antigen retrieved is performed using water-bath heating in the following buffers: in citrate buffer 465 
pH 6.0 (CC2 citrate-based buffer Ventana Medical Systems ROCHE Diagnostics) for TWIST1 466 
and in a CC1 buffer of pH 8 (CC1 = Tris-Borate/ EDTA, Ventana Medical Systems ROCHE 467 
Diagnostics) for TWIST2. Slides were then incubated 1h at RT with the rabbit polyclonal anti-468 
TWIST1 (1/50, ABD29, Millipore, Burlington; MA, USA); or 1h at 37°C with the sheep polyclonal 469 
anti-TWIST2 (1/200, AF6249, R&D Systems, Minneapolis, MN, USA) in Antibody Diluent 470 
Buffer from Ventana Medical Systems, ROCHE Diagnostics. The detection kit for the 471 
antibodies is the UltraView DAB detection Kit (Ventana Medical Systems Inc./ Roche 472 
Diagnostic). A counter-staining of the nuclei was used for 12 minutes by Hematoxylin. 473 
Immunostaining scores (0–4) were established for each stained tissue by semi-quantitative 474 
optical analysis by two independent investigators blinded for clinical data. The percentage of 475 
positive cells in each sample was scored as follows: 0, all cells negative; 1+, up to 25% of cells 476 
were positive; 2+, 26% to 50%; 3+, 51% to 75%; 4+, more than 75%.  477 
Cell culture   478 
The established human MNA NB cell lines (SK-N-Be2c and LAN-1) were obtained from their 479 
lab of origine58,59. Authentication of SK-N-Be2c and LAN1 cell lines was performed by 480 
microsatellite short tandem repeat analysis before starting the transduction experiments 481 
(Microsynth, Switzerland). The no-MNA NB1-M primary cells were derived in our laboratory 482 
from a bone marrow tissue recovered at the diagnosis from a patient with NB at the 483 
Hematology Oncology Unit of the University Hospital of Lausanne, Switzerland48. All cell lines 484 
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were cultured in Dulbecco’s modified Eagle’s medium (D-MEM) (Gibco, Paisley,UK), 485 
supplemented with 1% penicillin/streptomycin (Gibco) and 10% heat inactivated Fetal Calf 486 
Serum (FCS) (Sigma-Aldrich, St. Louis, Missouri, USA) and under standard culture conditions 487 
in humidified incubator at 37°C with 5% CO2.  488 
TWIST1 knock out through CRISPR/Cas9 technology 489 
Two sgRNAs targeting the first exon of the TWIST1 gene were chosen in the published sgRNA 490 
library60. Oligos were designed as follow: sgTWIST1-1: forward 5’-491 
CACCGCGGGAGTCCGCAGTCTTACG-3’; reverse 5’-492 
AAACCGTAAGACTGCGGACTCCCGC-3’; sgTWIST1-2: forward 5’- 493 
CACCGCTGTCGTCGGCCGGCGAGAC-3’; reverse 5’-494 
AAACGTCTCGCCGGCCGACGACAGC-3’. The lentiviral vector lentiCRISPR v261 was 495 
obtained from Adgene (Cambridge, USA). LentiCRISPR v2-sgTWIST1 plasmids were 496 
constructed according to the manufacturer’s instructions (Adgene), and used to transduce 497 
Control cells. Virus production and lentiviral infections were performed as previously 498 
described62. Transduced SK-N-Be2c, LAN-1 and NB1-M cells were selected 24 h post-499 
infection with either 5 μg/ml for SK-N-Be2c or 1 μg/ml for LAN-1 and NB1-M cells of puromycin 500 
(Gibco). Clones were isolated by limiting dilution cloning in a 96-wells plate from the Control 501 
and sgTWIST1 #1 of LAN-1 and SK-N-Be2c cell lines. Only clones derived from a single colony 502 
were selected and further screened by Immunoblotting. To avoid potential problems caused 503 
by variability during single-cell clonal expansion, we pooled 5 and 7 clones for the Control and 504 
sgTWIST1 SK-N-Be2c cells, respectively; for the LAN-1 cells, 6 clones were pooled for both 505 
Control and sgTWIST1 cells. SK-N-Be2c-Control and sgTWIST1 pools of cells were further 506 
transduced with a lentiviral vector expressing the mCherry gene (Ex-NEG-Lv244 from 507 
GeneCopoeiaTM). These cells expressing the mCherry gene were used for the ortho_2 and the 508 
sc xenograft experiments. In addition, genome editing in SK-N-Be2c sgTWIST1 cells was 509 
verified by NGS sequencing. Briefly, PCR amplicons were designed across the TWIST1 510 
genomic regions targeted by the sgRNAs to examine generation of indels. A first PCR of 20 511 
cycles was performed using the primers Twist1-nest-F: 5’-512 
GCAAGAAGTCTGCGGGCTGTGG-3’ and Twist1-nest-R: 5’-513 
GGATGATCTTCCGCAGCGCG-3’, followed by purification with QIAquick PCR purification kit 514 
(QIAGEN). Then we run a second PCR of 10 cycles with nested primers containing Illumina 515 
overhang adapter sequences: Illumina-P5-Twist1-F: 5’-516 
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG AAGAAGTCTGCGGGCTGTGGCG-3’; 517 
Illumina P7-Twist1-R: 5’-518 
GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCGCTCCCGCACGTTGGCCATG-3’. 519 
Both PCR were performed using the 2xKAPA HiFi HotStart ReadyMix as follow: 95°C for 5 520 
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minutes, 10 cycles at 98°C for 20 s, 73°C for 30 s, 72°C for 30 s; then 72°C for 5 min. Finally, 521 
a third PCR was performed to attach Illumina adaptors and barcodes to samples according to 522 
manufacturer’s instructions. Amplicons were purified by using AMPure XP (Beckman Coulter, 523 
Indianapolis, USA), and sequenced with a MiSeq Micro 300 (Illumina Inc., San Diego, USA) at 524 
the Lausanne Genomics Technologies Facility (GTF) 525 
(https://wp.unil.ch/gtf). After high throughput sequencing reads, PCR amplicons were checked 526 
for indels using CRISPResso (https://crispresso.pinellolab.partners.org). The results of the 527 
sequencing of the bulk population of SK-N-Be2c-sgTWIST1 cells, the 7 derived clones, and 528 
the 4 sgTWIST1 ortho_1 tumors are shown in Supplementary Data 11. Surprisingly, in all the 529 
sgTWIST1 clones we detected the same three main indels. Note that three alleles found in the 530 
SK-N-Be2c cells, indicating a triploidy of this genomic region as previously described63.  531 
Neurosphere Assay 532 
NB cells (2x104 cells/ml) were cultured in Neural Crest Stem Cell culture medium (NCSC) 533 
[DMEM/F12 (Gibco)  supplemented with 1 % penicillin/streptomycin (Gibco), 2 % B27 (Gibco), 534 
20 ng/ml human recombinant bFGF (Peprotech, Rocky Hill, USA), 1% N2 (Gibco), 2-535 
Mercaptoethanol 50µM (AppliChem, Darmstadt, Germany) 15% Chicken Embryo Extract, 20 536 
ng/ml IGF-1 (Peprotech), Retinoic Acid 110 nM], using poly-Hema-coated six wells plates to 537 
prevent cell adhesion. After 7 days in culture, pictures of sphere were taken using an Olympus 538 
IX53 inverted microscope (Olympus, Shinjuku, Japan) and acquired with the Olympus 539 
cellSense imaging software. Spheres were dissociated with StemPro Accutase Cell 540 
Dissociation Reagent (Gibco, A11105-01) and the number of cells recovered after the 541 
dissociation of spheres was determined using the trypan blue exclusion method.  542 
Proliferation assay 543 
Briefly, 1.2*104 MNA (SK-N-Be2c and LAN-1) and 3*104 no-MNA (NB1-M) cells were seeded 544 
in quadruplicate in 96-wells plate in DMEM/FCS. Cell proliferation was assessed using the 545 
CellTiter 96® Aqueous Non-radioactive Cell proliferation Assay (Promega, Madison, WI, USA) 546 
according to the manufacturer’s protocol.  547 
In vivo studies 548 
Animal experiments were carried out with athymic Swiss nude mice (Crl:NU(Ico)-Foxn1nu; 549 
Charles River Laboratory, France) in accordance with established guidelines for animal care 550 
of the Swiss Animal Protection Ordinance and the Animal Experimentation Ordinance of the 551 
Swiss Federal Veterinary Office (FVO). Animal experimentation protocols were approved by 552 
the Swiss FVO (authorization numbers: VD2995 and VD3372). All reasonable efforts were 553 
made to reduce suffering, including anesthesia for painful procedures. For surgical procedures, 554 
mice were anaesthetized using isoflurane (Baxter, Deerfield, IL, USA) and received 555 
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paracetamol as analgesia the day before the surgery. Orthotopic implantations were performed 556 
as previously described64 with slight modifications: 5x105 (ortho_1, 6 mice/group) and 5x104 557 
(ortho_2, 12 mice/group) SK-N-Be2c cells were resuspended in 10 μl of PBS and injected in 558 
the left adrenal gland after a small incision above the left kidney. Tumor growth was followed 559 
by ultrasound every 7 to 14 days at the Cardiovascular Assessment Facility (University of 560 
Lausanne). For subcutaneous implantation, groups of 5 mice were injected in the right flank 561 
with 2.5x105 cells suspended in 200 µl 1:1 mix of DMEM and BD MatrigelTM Basement 562 
Membrane Matrix (BD Biosciences, Bedford, MA, USA). The grafted animals were then weekly 563 
monitored with calipers for tumor growth assessment. The tumor volume was calculated using 564 
the formula: volume = 4/3 × π × (depth × sagittal × transversal)/6 for ortho tumors; and volume 565 
= (length x width2)/2 for sc tumors. For both orthotopic and subcutaneous implantations, mice 566 
with tumor volumes around ~1000 mm3 were sacrificed using CO2. Tumors and organs (lungs, 567 
liver) were cut into pieces and snap frozen in liquid nitrogen or fixed in formol and embedded 568 
in paraffin (lungs, liver, kidneys and spleen). 569 
RNA isolation 570 
Total RNA from cell lines and tumors was extracted using RNeasy kit (Qiagen, Hilden, 571 
Germany). RNA concentration was quantified using a Nanodrop (Agilent Technologies, 572 
Wilmington, DE, USA). For the RNA sequencing, RNA was quantified using Qubit Fluorometer 573 
(Life Technologies, Carlsbad, CA, USA). 574 
RNAseq library preparation 575 
RNAseq was performed at the iGE3 Genomics platform (University of Geneva, 576 
https://ige3.genomics.unige/ch) using standard techniques RNA integrity was verified using 577 
the Agilent 2100 Bioanalyzer system (Agilent Technologies). The total RNA ribo-zero gold kit 578 
from Illumina was used for the library preparation with 1 µg or 500 ng of total RNA as input for 579 
cells (n=3 biological replicates/group) and tumors (n=4/group), respectively. Library molarity 580 
and quality were assessed with the Qubit and Tapestation using a DNA High sensitivity chip 581 
(Agilent Technologies). Libraries were pooled at 2 nM and loaded for clustering on 1.5 lanes 582 
for cells and 1.5 lanes for tumors of a Single-read Illumina Flow cell. Reads of 100 bases were 583 
generated using the TruSeq SBS chemistry on an Illumina HiSeq 4000 sequencer. 584 
Bioinformatics analysis of RNAseq data 585 
For all samples, fastq files with 100 nucleotides long single-end reads were mapped with STAR 586 
version 2.5.2b on both the Human genome version Hg19 and the Mouse genome version 587 
Mm10, simultaneously. The following options were changed from the default parameters: --588 
outSAMmultNmax 50; --outFilterMatchNminOverLread 0.4;   --quantMode TranscriptomeSAM. 589 
Transcriptome annotations in gtf format for both organisms were downloaded from the 590 
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gencode website (https://www.gencodegenes.org/). Reads mapped on either the Human or 591 
the Mouse transcriptome were then parsed and split in one file per organism with an in-house 592 
perl script. Reads with matches on both Human and Mouse were discarded from the Mouse 593 
file. Per-gene counts and rpkm were then extracted independently for each organism using 594 
rsem version 1.3.0.  All RNAseq per-gene data quality checks and analysis were done in R. 595 
Mouse and Human data were analyzed independently, but following the same protocol. Protein 596 
coding genes with a log2(rpkm) value above 1 in at least one sample were kept (13742 genes 597 
in SK-N-Be2c for Human data; 14538 for Mouse data). Principal Component Analysis were 598 
done using the normalized log2 (rpkm) values. Clustering analysis were performed on the 599 
normalized log2 (rpkm) values using euclidean distance measures and the ward.D2 600 
agglomeration method. Differential analyses were performed using the raw counts in DESeq2 601 
package version 1.26.0. For each comparison, the cutoffs for fold-change (in log2) and 602 
adjusted p values to call differentially transcribed genes were set to 1 and 0.05 for Human, 603 
respectively, and to 0.5 and 0.05 for Mouse, respectively. Heat maps for sample correlations 604 
and for specific gene lists were generated using the heatmap.2 function from the gplots 605 
package version 3.0.1.2 on the log2 of DESeq2 normalized counts. Functional gene ontology 606 
analysis was performed by applying a hypergeometric test on selected genes lists against 607 
gene sets from KEGG, GO (Molecular Function, Biological Process and Cellular Component), 608 
REACTOME, and  BIOCARTA pathways. The p value cutoff for terms selection was set to 609 
0.001 for Human data and to 0.01 for Mouse data; only those terms with an adj p value below 610 
0.01 and 0.1 were taken into consideration for the graphical representation, respectively. For 611 
the GO analysis of the secretome, the lines containing multiple gene references were split 612 
before to apply the hypergeometric test on the resulting list of genes (673 terms in the 613 
secretome vs 678 terms in the transcriptome). For external RNAseq data analysis (Super 614 
series number: GSE80154; SubSeries number: GSE80153), fastq files from GSM2572350 to 615 
GSM2572355 corresponding to Be2C samples at 0 (DMSO: GSM2572350 to GSM2572352) 616 
and JQ1 24h (GSM2572353 to GSM2572355) were downloaded. These samples were then 617 
re-analyzed by applying the same protocol used for the local RNAseq data.  618 
Real-Time qPCR 619 
cDNA were prepared from 0.5 or 1 µg of RNA for the validation of human or murine genes, 620 
respectively using PrimeScriptTM reagent kit according to the manufacturer’s instruction 621 
(TAKARA Bio Inc., St.Germain-en-Laye, France). The expression level of selected genes was 622 
validated by semi-quantitative real-time PCR using primer pairs described in Supplementary 623 
Data 12 and the QuantiFast SYBR® green kit (Qiagen, Hilden, Germany). Cycling conditions 624 
were: 5 min at 95°C, 40 cycles of 10 sec at 95°C, 30 sec at 60°C, and 1 sec at 72°C with the 625 
Rotor Gene 6000 real-time cycler (Corbett, Qiagen). Gene expression levels were determined 626 
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by normalization to either HPRT1 (human genes) or β-actin (murine genes) housekeeping 627 
genes using the ΔCt method.  628 
Immunohistochemistry  629 
Histopathological analyses were performed on blocks embedded in paraffin at the Mouse 630 
Pathology Facility of Lausanne University (Epalinges, Switzerland) and at the Histology Core 631 
Facility of the EPFL (Lausanne, Switzerland). Thin tumor sections (3 µm thick) were de-waxed 632 
and rehydrated and then stained with hematoxylin and eosin; Gomori’s for reticulin or type III 633 
collagen detection, or IHC was performed using primary antibodies (Supplementary Data13). 634 
Staining were imaged using an Olympus BX43 light microscope and then acquired with the 635 
Olympus cellSense imaging software or using the EVOS5000 imaging system (Life 636 
Technologies); or whole slides were scanned using the NanoZoomer S60 Digital slide scanner 637 
C13210 (Hamamatsu, Japan) at the 20x magnification with a resolution of 0.46 µm/pixel. 638 
Visualization and analyses of the scans was performed using the QuPath imaging software 639 
(https://qupath.github.io). For the quantification of VCAN and α-mCherry, the entire surface 640 
either of the tumor or of three subsequent lung sections separated by a depth of 100 µm has 641 
been taken into consideration, respectively. Quantification was perfomed with the QuPath 642 
software according to the following pipeline: select a region of the tumor (magnification: 643 
12.48X), analyze, cell analysis, positive cell detection. Options modified from the default 644 
parameters: image type: Brightfield (other); detection image: optical density sum; intensity 645 
threshold parameters: threshold 1+: 0.3. 646 
Immunoblotting 647 
NB cells and SK-N-Be2c-derived ortho tumors were lysed in NP40 buffer (50 mM Tris-HCl pH 648 
8.0; 150 mM NaCl; 1% NP-40 and 1x protease inhibitor cocktail (Complete mini, EDTA-free, 649 
Roche, Mannheim, Germany). Cell lysates were centrifuged at 15’000 rpm at 4°C for 10 min. 650 
Supernatants were recovered and protein concentrations were measured using Bradford 651 
method (Bio-Rad Laboratories, Hercules, CA, USA). Equal amount of total protein lysate (40 652 
µg for DE genes validation; 50 µg for TWIST1 and MYCN validation) was loaded onto 4-15% 653 
precast polyacrylamide Mini-PROTEAN TGX gel (Bio-Rad Laboratories). Proteins were 654 
transferred to PVDF membrane (Immuno Blot,Bio-Rad Laboratories) and blocked with 3% 655 
nonfat dry milk in TBS-T 0.1%, incubated overnight at 4˚C with primary antibodies (Suppl Table 656 
10) and then for one hour with the appropriate secondary antibodies (Suppl Table 10). Proteins 657 
were imaged using either the WesternBright Sirius Kit or the WesternBright Quantum Kit 658 
(Advansta Inc., San Jose, CA, USA) and the Fusion FX Spectra multimodal imaging platform 659 
(Vilber Lourmat, Marne-la-Vallée, France). Quantification of immunoreactive bands was 660 
performed using the ImageJ software according to the following pipeline: analyze, gel, select 661 
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1 lane, plot lanes, manually define the area corresponding to each band, wand tool to quantify 662 
each selected area.  663 
Protein extraction for cell secretome analysis  664 
Three independent conditioned media (CM) samples were recovered from SK-N-Be2c Control 665 
and sgTWIST1 cells. Once cells reached ~75% of confluence, the medium was replaced with 666 
FBS- and phenol red-free DMEM (Gibco) in which cells were incubated for 24 hours. CM were 667 
first clarified by three centrifugation steps: 10’ at 300 x g; 10’ at 2000 x g cells; and 30’ at 10000 668 
x g at 4°C, and then concentrated using 15 ml Amicon spin filter cartridges (cutoff: 3 kDa, 669 
10705884-Merck Millipore, Burlington, MA, USA) by serial addition of 10 ml of CM and 670 
centrifugation at 4000 x g until 1.5 ml were left. After dilution in 100 mM Ammonium 671 
Bicarbonate buffer to the starting volume, the CM were re-concentrated by centrifugation at 672 
4000 x g, and these steps were repeated twice until 0.5 ml were left. Finally, aliquots were 673 
snap frozen in liquid nitrogen and used for the LC-MS analysis performed at the Protein 674 
Analysis Facility (University of Lausanne, Switzerland). CM were dried in a SpeedVac and then 675 
digested according to a modified version of the iST protocol 65. Pellets were resuspended in 676 
50 µl of modified iST buffer (2% sodium deoxycholate, 20mM DTT, 5mM EDTA, 200mM Tris 677 
pH 8.6) and heated at 95°C for 5 minutes. 50 µl of 160 mM chloroacetamide (in 10 mM Tris 678 
pH 8.6) were then added and cysteines were alkylated for 45 minutes at 25°C in the dark. After 679 
1:1 dilution with H2O, samples were adjusted to 3 mM EDTA and digested with 0.5 µg 680 
Trypsin/LysC mix (Promega #V5073) for 1h at 37°C, followed by a second 1h digestion with a 681 
second, identical aliquot of proteases. To remove sodium deoxycholate, two sample volumes 682 
of isopropanol containing 1% trifluoroacetic acid (TFA) were added to the digests, and the 683 
samples were directly desalted on a strong cation exchange (SCX) plate (Oasis MCX; Waters 684 
Corp., Milford, MA) by centrifugation. After washing with isopropanol/1% TFA, peptides were 685 
eluted in 250ul of 80% MeCN, 19% water, 1% (v/v) ammonia.  686 
Mass spectrometry analyses 687 
Tryptic peptides fractions were dried and resuspended in 0.05% TFA, 2% (v/v) acetonitrile, for 688 
mass spectrometry analyses. Tryptic peptide mixtures were injected on an Ultimate RSLC 689 
3000 nanoHPLC system (Dionex, Sunnyvale, CA, USA) interfaced to an Orbitrap Fusion 690 
Tribrid mass spectrometer (Thermo Scientific, Bremen, Germany). Peptides were loaded onto 691 
a trapping microcolumn Acclaim PepMap100 C18 (20 mm x 100 μm ID, 5 μm, 100Å, Thermo 692 
Scientific) before separation on a reversed-phase custom packed nanocolumn (75 μm ID × 40 693 
cm, 1.8 μm particles, Reprosil Pur, Dr. Maisch). A flowrate of 0.25 μl/min was used with a 694 
gradient from 4 to 76% acetonitrile in 0.1% formic acid (total time: 65 min). Full survey scans 695 
were performed at a 120’000 resolution, and a top speed precursor selection strategy was 696 
applied to maximize acquisition of peptide tandem MS spectra with a maximum cycle time of 697 
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0.6s. HCD fragmentation mode was used at a normalized collision energy of 32%, with a 698 
precursor isolation window of 1.6 m/z, and MS/MS spectra were acquired in the ion trap. 699 
Peptides selected for MS/MS were excluded from further fragmentation during 60s. 700 
Mass spectrometry data analysis and processing 701 
Tandem MS data were processed by the MaxQuant software (version 1.6.3.4)66 incorporating 702 
the Andromeda search engine67. The UniProt human reference proteome database of January 703 
2019 was used (73’950 sequences), supplemented with sequences of common contaminants. 704 
Trypsin (cleavage at K,R) was used as the enzyme definition, allowing 2 missed cleavages. 705 
Carbamidomethylation of cysteine was specified as a fixed modification. N-terminal acetylation 706 
of protein and oxidation of methionine were specified as variable modifications. All 707 
identifications were filtered at 2% FDR at both the peptide and protein levels with default 708 
MaxQuant parameters. After inspection and data QC based on the iBAQ68 values, the LFQ 709 
label-free values69 were used for protein quantitation. MaxQuant data were further processed 710 
with Perseus software70 for the filtering, log2-transformation, normalization of values and the 711 
statistical analyses. After removal of contaminants and reverse hits, intensity values were log2 712 
transformed. Only proteins identified by at least two peptides and quantitated in at least all 713 
three samples of one condition were retained for further analysis. Missing values were imputed 714 
with standard Perseus parameters (normal distribution with width 0.3 and down-shifted by 1.8 715 
SD). An unpaired T-test was used to determine significant changes, corrected for FDR with 716 
the Benjamini-Hochberg method and a threshold q-value at 0.01. Imputed values were 717 
subsequently removed from tables. Gene Ontology functional analysis were performed as 718 
previously described in the “Bioinformatics analysis” section, after splitting the lines containing 719 
multiple genes references.  720 
Statistical analysis 721 
All statistical analyses were performed using GraphPadPrism 8.3.0 (GraphPad Software Inc., 722 
San Diego, CA, USA). D’Agostino-Pearson normality test was performed for each data set, 723 
and depending on data distribution, they were analyzed with unpaired two-tailed parametric t-724 
test or non parametric Mann-Whitney test to compare two different conditions. 725 
Reporting summary. Further information on research design is available in the Nature 726 
Research Reporting Summary linked to this article.  727 
Data availability 728 
All data generated during this study are included in this article (and its Supplementary 729 
Information files). The RNAseq, proteomics and image corresponding datasets can be 730 
accessed at the GEO public repository using the accession number GSE160765; at the 731 
Proteomics Identifications Database (PRIDE) using the accession number PXD024200; and 732 
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at the Zenodo repository with the doi: 10.5281/zenodo.4543478, respectively. The RNAseq 733 
data of SK-N-Be2c JC1 samples were obtained from GEO, using the accession number 734 
GSE80153. The relevant data that support the findings of this study are available from the 735 
corresponding author upon reasonable request. Source data are provided with this paper. 736 
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Figure 1. TWIST1 RNA expression is associated with poorer outcome of NB patients. (a-935 
c) Analysis of TWIST1 expression in the SEQC dataset of primary NB tumors. (a) Kaplan-936 
Meier OS curve associated with TWIST1 expression. Expression cutoff: 44.441.  (b) Box-and-937 
whisker plots of TWIST1 expression in tumors with MNA or without MNA (no-MNA). (c) 938 
Kaplan-Meier EFS curves showing the stratification of patients according to MYCN status and 939 
TWIST1 expression (high or low).  940 
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 941 
 942 
Figure 2. TWIST1 and TWIST2 display an opposite protein expression profile in a NB 943 
tissue microarray. (a) TWIST1 and TWIST2 protein expression were analyzed by IHC using 944 
a NB TMA containing 97 tumor sections: 72 primary tumors, 25 matched metastases and 44 945 
matched control normal tissues (i.e. SG). Representative images of TWIST1 and TWIST2 IHC 946 
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staining are shown for each indicated category. Magnification 100x (left panels) and 400x (right 947 
panels); scale bares=100 µm. (b) Bar graphs showing the median scores (ms) ± SD of TWIST1 948 
and TWIST2 IHC staining for different comparisons (see Table 1). Statistical analysis was done 949 
using parametric Student’s t-test.   950 
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 951 
Figure 3. TWIST1 KO reduces the neurosphere forming capacities of NB cells in vitro 952 
and the tumor growth capacities of SK-N-Be2c cells in vivo. (a) Upper panel: 953 
representative images (scale bar 200 µm) showing the size and shape of primary 954 
neurospheres of Control and sgTWIST1 NB cells after 7 days in culture. Lower panel: the 955 
numbers of cells obtained after dissociation of Control and sgTWIST1 primary neurospheres 956 
are plotted in bare graphs as individual values for each independent experiments and mean ± 957 
SD (n=5 experiments performed in duplicates). Mann Whitney test: *p=0.0317 for SK-N-Be2c; 958 
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*p=0.0159 for LAN-1 and NB1-M. (b) Kaplan-Meier survival curves of athymic Swiss nude mice 959 
implanted with SK-N-Be2C-Control or -sgTWIST1 cells. Mice were sacrificed once tumors 960 
reached the volume of 1000 mm3 and 500 mm3 for ortho_1 and ortho_2 experiments, 961 
respectively. Tumor take: ortho_1: 100% (6/6) in the Control group, 66.66% (4/6) in the 962 
sgTWIST1 group; ortho_2: 89% (8/9) in the Control group, 83% (10/12) in the sgTWIST1 963 
group. Median survival in the Control vs sgTWIST1 group: 26 vs 44 days for ortho_1 964 
(**p=0.0027); 49 vs 78 days for ortho_2 (**p=0.0016). Gehan-Breslow-Wilcoxon test. (c)Tumor 965 
growth (mean tumor volumes ± SD) for ortho_1 experiment. Multiple t-test (Holm-Sidak, 966 
α=0.05, without assuming a consistent SD): **p=0.0037. (d) Time for tumor initiation (left) and 967 
tumor growth (right) in the ortho_2 experiment (mean days ± SD). Tumor initiation correspond 968 
to the number of days required to measure an AG volume > 10 mm3 (mean Control: 41.38 969 
days, sgTWIST1: 64.10 days, *p=0.0192). Time for tumor growth was calculated as the 970 
number of days at sacrifice minus the number of days for tumor initiation (mean Control: 9.25 971 
days, sgTWIST1: 22.50 days, ***p=0.0006). Unpaired t-test. 972 
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is 
The copyright holder for this preprintthis version posted March 22, 2021. ; https://doi.org/10.1101/2021.03.22.435811doi: bioRxiv preprint 
 973 
Figure 4. TWIST1 KO produces tumor with a less aggressive phenotype and impairs the 974 
formation of the intrapulmonary macrometastases. (a) Representative images of H&E 975 
staining of ortho tumors and AG. H&E staining of both ortho-derived tumors depicted cells in 976 
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control tissues separated by thin fibro-vascular septs having irregular size and shape; no 977 
discernable/scarce cytoplasm; one or few prominent nucleoli; spindle-shaped cells with 978 
fusiform nuclei (black arrow) that tended to have a fascicular organization. Conversely, 979 
sgTWIST1 tumor cells were portrayed by a more regular size and shape (round to oval) with 980 
only slight irregularities, finely granular (“salt-and-pepper”) chromatin, small nucleoli and 981 
moderate/more discernible cytoplasm (scale bar: 125 µm for tumors; 600µm for AG). (b) 982 
Representative images of Gomori’s staining showing the architecture of the collagen 983 
III/reticulin fibers in ortho tumors and AG. Left panels: large views of tumor and AG sections; 984 
scale bars: 1 mm and 200 µm, respectively. Right panels: zoomed view of the region 985 
highlighted by a black circle, scale bars: 100 µm for both tumors and AG. (c) H&E and anti-986 
mCherry staining for pulmonary metastases detection in the lungs of ortho_2 mice. Upper 987 
panel: representative images of Control mice; lower panel: pictures of the unique 988 
macrometastasis detected in sgTWIST1 group of mice. (d) Quantification of metastases 989 
detected by IHC anti-mCherry within the parenchyma (intrapulmonary) of mice. Of note, no 990 
metastases were detected at the pleural surface and/or in mediastinal soft tissue 991 
(peripulmonary). Data are plotted in a bar graph showing individual values and mean ± SD for 992 
micrometastases (100-500 µm2: p=0.2257; 500-1000 µm2: p=0.1855) and for 993 
macrometastases (>1000 µm2, **p= 0.0041). Mann-Whitney test. Percent of mice with 994 
macrometastases = 75% in the Control group; 10% in the sgTWIST1 group.  995 
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 996 
Figure 5. The biological pathways deregulated by TWIST1 KO are distinct from those 997 
mediated by MYCN shut down. (a) PCA samples repartition using the VST-normalized 998 
counts. PCA1 and PCA2 are 63% and 23% of total variation, respectively. (b) Volcano plots 999 
showing the distribution of the DE genes according to FC (log2) and adj p value between the 1000 
SK-N-Be2c-Control and –sgTWIST1 ortho_1-derived xenografts. Genes with False Discovery 1001 
Rate (FDR) < 0.05 and absolute value (av) of log2(FC) ≥ 1 were considered as DE; in red 1002 
genes with av of log2(FC) ≥2, in black genes with av of log2(FC) ≥ 1 and <2. Positive and 1003 
negative x-values represent genes either up- or down-regulated by TWIST1, respectively. (c). 1004 
Illustration of the biological processes gene sets found enriched by GO analyses (GO BP) in 1005 
the DE genes following TWIST1 KO for both SK-N-Be2c cells (left panel) and ortho_1 tumors 1006 
(right panel). Data are reported as the repartition (in %) of the diverse pathways identified with 1007 
a FDR < 0.01 (n=111 for cells, n=92 for tumors). (d) Illustration of the GO BP gene sets found 1008 
enriched in the DE genes in SK-N-Be2c cells upon JC1-medited MYCN shutdown. RNAseq 1009 
data of SK-N-Be2c cells treated with JC1 during 24h or DMSO as control were uploaded 1010 
(GSE80154, see Methods) (Zeid et al.). Genes with False Discovery Rate (FDR) < 0.05 and 1011 
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absolute value (av) of log2(FC) ≥ 1 were considered as DE. Data are reported as the repartition 1012 
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 1037 
Figure 6. Identification of a TWIST1-associated gene signature correlating with poor 1038 
prognosis in NB. (a) Heatmap showing 763 common genes either correlated or anti-1039 
correlated with TWIST1 in NB patients and DE in the ortho_1 tumors. The binary side color 1040 
bar going from green to red indicates DE genes anti-correlated (R<-0.225, green) or correlated 1041 
(R>0.225, red) with TWIST1 in the SEQC dataset; the  black bar shows the genes that have 1042 
both FC and R values either positive or negative representing the TWIST1-signature, and the 1043 
grey bar the genes that have opposite FC and R values (not included in the signature). (b) 1044 
Volcano plot showing the distribution of the 489 genes of the TWIST1-signature according to 1045 
their log2(FC) in SK-N-Be2c ortho_1 tumors and R values in the SEQC dataset . (c) Heatmap 1046 
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hierarchical clustering showing different expression pattern relative to TWIST1-signature 1047 
genes generated using the R2 Platform (http://r2.amc.nl). Columns represent patients 1048 
annotated in the SEQC cohort; the 489 genes are clustered hierarchically along the left y-axis. 1049 
Clinical criteria taken into consideration (risk groups, tumor stages, and MYCN amplification 1050 
status) are indicated on the top by color codes. The heat map indicates in red, blue and white 1051 
a high, low and a medium level of gene expression (z-score), respectively. The blue-white-red 1052 
color bars depicted at the bottom of the heatmap represent the z-score of TWIST1_Up and 1053 
TWIST1_Down gene sub-lists of the signature, as well as for the z-score of the whole signature 1054 
(weighted). (f-g) Kaplan-Meier OS and EFS survival curves according to the expression level 1055 
of the TWIST1-signature in both the complete SEQC dataset (f) and in the sub-cohort of 1056 
patients without MNA (no-MNA) (g). Expression cutoff: 0.20 (f) and -0.05 (g). 1057 
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Figure 7. Validation of TWIST1-mediated deregulation of selected genes belonging to 1060 
the TWIST1 signature in the ortho_1 tumors. (a) Bar plots showing the distribution of the 1061 
top 20 up- and 20 down-regulated genes of the TWIST1 signature ordered according to their 1062 
log2(FC). In red, genes that were selected for the validation at both RNA and protein levels. 1063 
Gene names in brackets indicate up-regulated genes involved in the EMT process, TME 1064 
organization, proliferation and apoptosis; and down-regulated genes that are known to be 1065 
tumor suppressor genes or associated with good prognosis in NB. (b) Heatmap showing the 1066 
relative RNA expression (z-score) determined by RNAseq of the selected genes in ortho_1 1067 
tumors.  (c)  RNA expression levels of the TWIST1 target genes relative to the reference gene 1068 
HPRT1 in the ortho_1 tumors analyzed by RT-qPCR are plotted as individual values with mean 1069 
± SD. Control n= 6 ; sgTWIST1 n= 4. Mann Whitney test: *p=0.0286 for all comparisons. (d) 1070 
Upper panel: Immunoblotting for TRIM28, ADAMTS19, PCOLCE, ADAMTS19, SYT13 and 1071 
PIRT (β-ACTIN as the loading control); lower panel: densitometric quantifications of 1072 
immunoreactive band densities. Expression relative to β-ACTIN were plotted as individual data 1073 
with mean ± SD. Control n= 5; sgTWIST1n= 4 . Mann Whitney test: *p= 0.0317 for ADAMTS19; 1074 
*p= 0.0159 for the other proteins.    1075 
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 1076 
Figure 8. Identification of a TWIST1-mediated-tumor-stroma signature associated with 1077 
poor outcome in NB. (a) Bar plot illustrating of the 77 DE genes representing the TWIST1-1078 
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tumor-stroma signature in SK-N-Be2c ortho_1 tumors. Genes were classified according to their 1079 
log2(FC) in three main categories: growth factors (including the TGF and FGF families). 1080 
cytokines (TNF and INF families, chemokines and interleukins), and integrins and their ligands 1081 
(ITG, collagens and laminins). (b) Kaplan-Meier OS and EFS curves of NB patients of the 1082 
SEQC dataset according to the expression level of the TWIST1-tumor-stroma signature. 1083 
Expression cutoff for both curves: 0.10. (c) Volcano plot showing the distribution of the DE 1084 
protein secreted by SK-N-Be2c cells according to the delta label-free quantification (∆LFQ = 1085 
LFQ SK-N-Be2c Control – LFQ SK-N-Be2c sgTWIST1) intensities (Log2) and the adjusted p 1086 
values with an FDR ≤ 0.02 analyzed by LC-MS/MS (n= 3 biological replicates for each group). 1087 
(d)  3D scatterplot showing DE terms in the cell secretome in common with the tumor 1088 
transcriptome (magenta, n=55), the cell transcriptome (green, n=75), or both transcriptomes 1089 
(blue, n=131). (e) Bar plot showing the terms commonly deregulated between the TWIST1-1090 
tumor-stroma signature and both the cell transcriptome and secretome. Names in brackets are 1091 
for terms found to be DE in the secretome but not in the transcriptome of cells.  1092 
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 1093 
Figure 9. Identification of a TWIST1-associated myofibroblast signature. (a) Volcano plots 1094 
showing the distribution of the DE gene identified in SK-N-Be2c-Control and –sgTWIST1 tumor 1095 
stroma of ortho_1 xenografts relative to their log2(FC) and adjusted p value (FDR). Genes with 1096 
FDR < 0.05 and absolute value (av) of log2(FC) ≥ 0.5 were considered as DE. Genes identified 1097 
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as the Myofibroblast signature are indicated in red (n=36). The green square is for the gene 1098 
Marco. (b)  Bar graph showing the  biological processes, cellular components and REACTOME 1099 
pathways identified by GO analysis of the 89 DE genes of the murine stroma, listed according 1100 
to their adjusted p value. (c) mRNA expression levels of the selected myofibroblast genes and 1101 
Marco relative to β-actin as by RT-qPCR. Data are plotted as individual values with mean ± 1102 
SD. Mann Whitney test: *p= 0.0286. Ortho_1 Control and sgTWIST1 tumors: n=4.  (d)  IHC for 1103 
the cancer-associated fibroblast marker Fibroblasts Activation Protein (FAP) on ortho_1 1104 
Control and sgTWIST1 tumors. Representative images of FAP positive cells characterized by 1105 
spindle or fusiform morphologies and haphazardly arranged are shown (400x, scale bar: 20 1106 
µm). 1107 
 1108 
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 1110 
Figure 10. PPI network for the TWIST1-associated tumor-stroma signature and the DE 1111 
stromal genes.  Analysis of the protein-protein interactions between the TWIST1-tumor-1112 
stroma signature (n= 77 genes) and the DE murine stromal genes (n=89). Direct (physical) as 1113 
well as indirect (functional) interactions analyzed using the String website. All the basic and 1114 
advanced default settings have been kept but the minimum required interaction score, that has 1115 
been changed in high confidence (0.7); and the network display options, hiding the 1116 
disconnected nodes in the network. PPI enrichment p value: <1.0e-16. Murine stromal genes 1117 
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 1123 
 1124 
Table 1. Composition of the TMA and expression of TWIST1 and TWIST2 in NB primary 1125 
tumors, metastases and control tissues. SG: sympathetic ganglia, INSS: International 1126 
Neuroblastoma Staging System, n: number of cases. Median score means average tumor 1127 
score, as established by semi-quantitative analysis of the immunostaining. Student’s t-test: 1128 
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Table 2. Summary of myofibroblast markers and principal muscle structure-specific genes 1137 
identified in the myofibroblast signature of ortho_1 tumors (labeled in red in Fig. 9a) with their 1138 
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Supplementary Figure 1  1 
 2 
 3 
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Supplementary Fig. 1. TWIST1 and TWITS2 RNA expression in NB cells and tumors. (a) 4 
Box plot showing the mRNA expression levels of TWIST1 (left) and TWIST2 (right) in a panel 5 
of 40 cancer cell lines in the CCLE database. The numbers in the brackets correspond to the 6 
numbers of cell lines per tumor types. (b) Kaplan-Meier OS curve associated with TWIST1 7 
expression in the Kocak dataset of primary NB tumors (expression cutoff = 6701.9) (n=476 8 
with survival data). (c) EFS associated with TWIST1 expression in the SEQC (left panel, 9 
expression cutoff: 44.441) and Kocak (right panel, expression cutoff = 6701.9) datasets. (d-e) 10 
Box-and-whisker plots of TWIST1 expression in MNA and no-MNA tumors (d); and in tumors 11 
with distinct INSS stages in the indicated datasets (e). (f) Kaplan-Meier EFS curves showing 12 
the stratification of patients of the SEQC dataset according to the risk classification (high-risk: 13 
HR; low-risk: LR) and TWIST1 expression (high or low). (g) OS and EFS according to TWIST2 14 
expression in the SEQC (left panels, expression cutoff: 1010) and Kocak (right panels, 15 
expression cutoff: 86.0) datasets. (h) Box-and-whisker plots of TWIST2 expression in no-MNA 16 
and MNA tumors in the SEQC and Kocak datasets.  17 
 18 
  19 
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Supplementary Figure 2  20 
 21 
 22 
Supplementary Fig. 2.  Validation of the CRISPR/Cas9-mediated TWIST1 KO and its 23 
impact on NB cell proliferation in vitro. (a) Immunoblotting for the detection of TWIST1 24 
protein expression and β-actin (as the loading control) in the bulk populations of NB cells before 25 
(Parental) and after the lentiviral infection: Control vector, sgTWIST1#1 (sgTWIST1, from now 26 
on) and sgTWIST1#2. (b)  TWIST1 protein expression in the LAN-1 and SK-N-Be2c pool of 27 
clones for Control and sgTWST1 (see Matherial&Methods). (c) Cell proliferation of Control and 28 
sgTWST1 NB cell lines measured by MTS/PMS assay from 24h to 96h. Mean OD 490nm ± 29 
SD of three (SK-N-Be2c) and four (LAN-1 and NB1-M) independent experiments performed in 30 
quadruplicates are shown. Statistical analysis was done using the Holm-Sidak multiple t-test 31 
(α=0.05), without assuming a consistent SD. *p= 0.0376 in SK-N-Be2c. 32 
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Supplementary Figure 3 34 
 35 
 36 
Supplementary Fig. 3. TWIST1 KO diminishes the tumor growth and invasive capacities 37 
of SK-N-Be2c cells. (a) Kaplan-Meier survival curve of mice implanted subcutaneously with 38 
SK-N-Be2c-Control or -sgTWIST1 cells. Mice were sacrificed once tumors reached 39 
approximately 700 mm3. Tumor take: 100% (5/5) in both groups. Median survival in the Control 40 
vs sgTWIST1 groups: 26.5 vs 59 days. Gehan-Breslow-Wilcoxon test: ***p=0.0002. (b) Tumor 41 
growth curve for the sc experiment. Data are plotted as the mean tumor volume ± SD. Mann-42 
Whitney t-test: **p= 0.0079 at both 22 and 25 days. (c) Representative ultrasound images of 43 
tumor cell intravasation in the vena cava of 2 distinct ortho_1 and ortho_2 Control mice.  44 
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Supplementary Fig. 4. TWIST1 KO affects the the Collagen III/reticulin network 50 
organization. (a)   Representative images of Gomori’s staining showing the ECM architecture 51 
of Control and sgTWIST1 sc tumors (scale bars: top 1mm; bottom 100µm) as compared to the 52 
normal AG (scale bars: top 200 µm; bottom 100 µm). (b) Graphs illustrating the mean tumor 53 
volumes at sacrifice ± SD. Ortho_1: mean Control= 1343 mm3, n=6; sgTWIST1= 587 mm3, 54 
n=4; Mann-Whitney test: p= 0.257. Ortho_2:  mean Control= 430 mm3, n= 8; sgTWIST1= 397 55 
mm3, n=10; unpaired t-test: p= 0.. SC: mean Control: 737 mm3, n=5; sgTWIST1= 757 mm3, 56 
n=5; Mann-Whitney: p>0.999.  57 
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Supplementary Figure 5  59 
 60 
Supplementary Fig. 5. Distinct transcriptional programs are affected upon TWIST1 KO 61 
and MYCN shut down. (a)  Volcano plots showing the distribution of the gene expression fold 62 
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changes and adjusted p value for the DE genes in SK-N-Be2c-Control versus SK-N-Be2c–63 
sgTWIST1 cells. Genes with False Discovery Rate (FDR) < 0.05 and absolute value (av) of 64 
log2(FC) ≥ 1 were considered as DE; in red genes with av of log2(FC) ≥2, in black genes with 65 
av of log2(FC) ≥ 1 and <2. Positive and negative x-values represent genes either up or down-66 
regulated by TWIST1 respectively. (b). Illustration of the cellular components gene sets found 67 
enriched by GO analyses (GO CC) in the DE genes following TWIST1 KO for both SK-N-Be2c 68 
cells (left panel) and ortho_1 tumors (right panel). Data are reported as the repartition (in %) 69 
of the diverse pathways identified with a FDR < 0.01 (n=58 for cells, n=48 for tumors). (c) 70 
Immunoblotting for MYCN protein and β-actin as control (upper panel) and densitometric 71 
quantification of MYCN expression relative to β-ACTIN (lower panel) in SK-N-Be2c-derived 72 
tumors of the 3  in vivo experiments. Expressions relative to β-ACTIN were plotted as individual 73 
data with mean ± SD. Mann Whitney test. *p= 0.0159 in ortho_2 and sc. Ortho_1: n= 5 Control; 74 
n= 4 sgTWIST1; ortho_2 and sc: n= 5 Control; n= 5 sgTWIST1. (d) Illustration of the GO CC 75 
gene sets found enriched in the DE genes of SK-N-Be2c cells upon JC1-medited MYCN 76 
shutdown. RNAseq data of SK-N-Be2c cells treated with JC1are during 24h or DMSO as 77 
control were uploaded (GSE80154, see Methods) (Zeid et al.). Genes with False Discovery 78 
Rate (FDR) < 0.05 and absolute value (av) of log2(FC) ≥ 1 were considered as DE.  Data are 79 
reported as the repartition (in %) of the diverse pathways identified with a FDR < 0.01 (n=24).  80 
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Supplementary Figure 6  82 
 83 
Supplementary Fig. 6. Identification of a TWIST1-signature associated with poor 84 
survival in NB. (a)  Illustration of the 7737 genes correlated with TWIST1 expression in the 85 
SEQC dataset of NB primary tumors with the repartition of the R values. Source probeset: 86 
NM_000474; R p value cutoff: 0.01; Corr. multiple testing: Bonferroni. (b-c) Kaplan-Meier OS 87 
and EFS survival curves associated with the expression of the TWIST1-signature both in the 88 
complete Kocak cohort with survival data (n=476) (b) and in the no-MNA sub-cohort (n=405) 89 
(c). Expression cutoff: 0.03 for both curves.  90 
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Supplementary Figure 7  92 
 93 
 94 
Validation of TWIST1-mediated deregulation of selected TWIST1 target genes at the 95 
RNA level in SK-N-Be2c-derived tumors. (a-b) mRNA expression levels of the selected 96 
TWIST1 target genes relative to HPRT1 analyzed by RT-qPCR are plotted as individual values 97 
with mean ± SD for the indicated in vivo experiments. Numbers of tumors analyzed for ortho_2 98 
(a): Control n= 8, sgTWIST1 n= 10; and for sc (b): Control n= 4, sgTWIST1 n= 4. Statistical 99 
analysis was performed using Mann Whitney test for all genes but PCOLCE in ortho_2 100 
experiment (unpaired t-test: ****p<0.0001). Ortho_2: TRIM28: ****p=0.0001 2; VCAN: 101 
**p=0.0021; PDGFRA and ADAMTS19: ****p=0.0001; PIRT: *p=0.0146; SYT13: *p=0.0266; 102 
sc: TRIM28: *p=0.; VCAN, PDGFRA, ADAMTS19 and PIRT: *p=0.0286; SYT13: *p=0.0266.   103 
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Supplementary Figure 8 104 
 105 
 106 
Supplementary Fig. 8. Analysis of the protein expression levels of selected TWIST1 107 
target genes in SK-N-Be2c-derived tumors. (a) Upper panels: representative images of IHC 108 
for VCAN in the indicated tumors (scale bar =100 µm); lower panels: quantification of VCAN 109 
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staining (Qpath software on total area of each section). Mann-Whitney: ortho_1:**p=0.0095, 110 
n=6 Control and n=4 sgTWIST1; ortho_2: *p= 0.0155, n=8 Control and n=10 sgTWIST1; sc: 111 
**p=0.0079,  n=5 Control and n=5 sgTWIST1. (b-c). Relative protein expression as determined 112 
by immunoblotting for the selected genes in the ortho_2 (b) and the sc (c) tumors. Upper panel: 113 
Representative images of immunoblotting for TRIM28, PCOLCE, PIRT and SYT13 (β-ACTIN 114 
as the control); MW: molecular weight; lower panel: densitometric quantifications of 115 
immunoreactive band densities. Expressions relative to β-ACTIN were plotted as individual 116 
data with mean ± SD. Mann Whitney test: **p=0.0079 for all comparisons. Ortho_2  and sc: 117 
n=5 Control and n=5 sgTWIST1.  118 
119 
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is 
The copyright holder for this preprintthis version posted March 22, 2021. ; https://doi.org/10.1101/2021.03.22.435811doi: bioRxiv preprint 
Supplementary Figure 9  120 
 121 
 122 
Supplementary Fig. 9. Correlation between the TWIST1-tumor-stroma signature in the 123 
Kocak NB dataset and the outcome of patients. (a)  Kaplan-Meier plots showing the 124 
correlation between a high level of the paracrine signature expression and a poor OS and EFS 125 
of NB patients in the Kocak dataset. Expression cutoff for both curves: 0.14. (b) Illustration of 126 
biological processes (BP) found enriched by gene ontology analysis for the DE proteins in SK-127 
N-Be2c cell secretome. Data are reported as the repartition (in %) of the diverse BP identified 128 
with a FDR < 0.01 (n=50).  129 
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Supplementary Figure 10 131 
 132 
 133 
Supplementary Fig. 10. Validation of selected genes of the myofibroblast signature in 134 
the ortho_2 and sc tumors by real-time PCR. (a) Heatmap showing the RNA expression 135 
levels (z-score) of the Myofibroblasts signature selected genes as determined by RNAseq 136 
analysis in ortho_1 tumors. (b) mRNA expression levels for the selected myofibroblast genes 137 
and Marco relative to β-actin as determined by RT-qPCR. Data are plotted as individual values 138 
with mean ± SD. Mann Whitney test: Ortho_2: Ttn: *p= 0.0309; Marco: ****p<0.0001. Ortho_2 139 
tumors: Control n=8; sgTWIST1 n=10; sc tumors: Control n=4, sgTWIST1 n=4.  140 
 141 
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